AMGEN at the American Heart Association's (AHA) Scientific Sessions 2022

Welcome to the Amgen Medical Virtual Exhibit

Cardiometabolic Pipeline

PROFICIO Clinical Development Program-Introducing VESALIUS-CV

Evolocumab PROFICIO Program and Ongoing Trials Book

Learn about PROFICIO, Amgen’s program of clinical studies of evolocumab, including VESALIUS-CV, a global initiative exploring the potential of evolocumab for the prevention of first CV events. This is an investigational study. Evolocumab is not indicated for this intended use.

DOWNLOAD BOOKLET

Please note: Some of the information on this page may pertain to investigational drugs.